Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review

Continuous cultures of fused cells secreting antibody of predefined specificity

Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200

Trastuzumab emtansine for HER2-positive advanced breast cancer

Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532

Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

Govindan, R., Page, N. C., Morgensztern, D., Read, W. L., Tierney, R. M., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,844

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

Hidalgo, M. M., Amant, F. C., Biankin, A. V., Budínská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,797

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Phillips, G. D. L., Li, G., Dugger, D. L., Crocker, L., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,708

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,528

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S. M., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,444

Polymer Therapeutics: Concepts and Applications

Haag, R., & Kratz, F. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502113 · Cited by 1,119

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

Pro, B., Advani, R. H., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M. A., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 1,004

Cancer Stem Cell Markers in Relation to Patient Survival Outcomes: Lessons for Integrative Diagnostics and Next-Generation Anticancer Drug Development

Dzobo, K., Ganz, C., Thomford, N. E., & Senthebane, D. A. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0185 · Cited by 31

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer

Harel, E., Drake, P. M., Barfield, R. M., Lui, I., Farr-Jones, S., Veer, L. V., Gartner, Z. J., Green, E. M., Lourenço, A. L., Cheng, Y., et al. (2019) · Antibodies · doi:10.3390/antib8040054 · Cited by 30

Plant-made immunotoxin building blocks: A roadmap for producing therapeutic antibody-toxin fusions

Knödler, M., & Buyel, J. F. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107683 · Cited by 29

Current targeted therapies in lymphomas

Chung, C. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz202 · Cited by 29

Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody–Drug Conjugate Exposure in Solid Tumor

Bussing, D., Sharma, S., Li, Z., Meyer, L. F., & Shah, D. K. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00584-y · Cited by 29

Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer

Zhang, J., Fan, J., Zeng, X. L., Nie, M., Chen, W., Wang, Y., Luan, J., Zhu, Z., Chang, X., Ju, D., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03349-1 · Cited by 29

Novel Method for Preparation of Site-Specific, Stoichiometric-Controlled Dual Warhead Conjugate of FGF2 via Dimerization Employing Sortase A-Mediated Ligation

Krzyścik, M. A., Opaliński, Ł., & Otlewski, J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00434 · Cited by 28

Adverse events of antibody–drug conjugates on the ocular surface in cancer therapy

Domínguez-Llamas, S., Caro, M., Mataix, B., Avilés-Prieto, J., Romero-Barranca, I., & Rodríguez-de-la-Rúa-Franch, E. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03261-y · Cited by 28

Antibody-Drug Conjugates: Patient and Treatment Selection

Makawita, S., & Meric‐Bernstam, F. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280775 · Cited by 27

Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

Chen, H., Yang, G., Xiao, J., Zheng, L., You, L., & Zhang, T. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.011 · Cited by 30

A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts

Coleman, O., Henry, M. A., O’Neill, F., Roche, S., Swan, N., Boyle, L., Murphy, J., Meiller, J., Conlon, N. T., Geoghegan, J., et al. (2018) · Proteomes · doi:10.3390/proteomes6040045 · Cited by 30

Design of S–S bond containing maleimide-conjugated closo -dodecaborate (SSMID): identification of unique modification sites on albumin and investigation of intracellular uptake

Ishii, S., Sato, S., Asami, H., Hasegawa, T., Kohno, J., & Nakamura, H. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob00584f · Cited by 27

ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies

Amani, N., Dorkoosh, F. A., & Mobedi, H. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191121145109 · Cited by 27

Monoclonal Antibody Targeting Sialyl-di-Lewisa–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential

Tivadar, S. T., McIntosh, R. S., Chua, J. X., Moss, R. S., Parsons, T., Zaitoun, A. M., Madhusudan, S., Durrant, L. G., & Vankemmelbeke, M. N. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0221 · Cited by 27

Smart chemistry for traceless release of anticancer therapeutics

Prange, C. J., Hu, X., & Tang, L. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122353 · Cited by 26

In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody–Drug Conjugates: Taking Advantage of Dual Labeling with 195mPt and 89Zr

Muns, J. A., Montserrat, V., Houthoff, H.-J., van der Schilden, K., Zwaagstra, O., Sijbrandi, N. J., Merkul, E., & van Dongen, G. A. M. S. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.206672 · Cited by 26

First clinical study of a pegylated diabody 124I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers

Scott, A. M., Akhurst, T., Lee, F.-T., Ciprotti, M., Davis, I. D., Weickhardt, A. J., Gan, H. K., Hicks, R. J., Lee, S. T., Kocovski, P., et al. (2020) · Theranostics · doi:10.7150/thno.49422 · Cited by 27

Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells

Hellmann, I., Waldmeier, L., Bannwarth-Escher, M.-C., Maslova, K., Wolter, F. I., Grawunder, U., & Beerli, R. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02490 · Cited by 26

PEGylation of Dipeptide Linker Improves Therapeutic Index and Pharmacokinetics of Antibody-Drug Conjugates

Long, J., Shao, T., Wang, Y., Chen, T., Chen, Y., Chen, Y., Wang, Q., Xiong, Y., Yu, J., He, K., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00392 · Cited by 25

Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B

Cheung, L. H., Zhao, Y., Álvarez‐Cienfuegos, A., Mohamedali, K. A., Cao, Y. J., Hittelman, W. N., & Rosenblum, M. G. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1333-6 · Cited by 25

Triple-negative breast cancer: from none to multiple therapeutic targets in two decades

Carvalho, F. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1244781 · Cited by 26

Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers- an overview

Goli, N., Bolla, P. K., & Talla, V. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.08.022 · Cited by 26

Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery

Borbély, A., Figueras, E., Martins, A., Bodero, L., Dias, A. R. M., Rivas, P. L., Pina, A., Arosio, D., Gallinari, P., Frese, M., et al. (2019) · ChemistryOpen · doi:10.1002/open.201900110 · Cited by 24

A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors

Zhang, S., Zheng, C., Zhu, W., Peng, X., Zhou, D., Huang, C., & Zheng, D. (2019) · Theranostics · doi:10.7150/thno.33598 · Cited by 23

Antibody-drug conjugates for the treatment of ovarian cancer

Calo, C. A., & O’Malley, D. M. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1776253 · Cited by 22

Immunotoxins: Targeted Toxin Delivery for Cancer Therapy

Mei, X., Chen, J., Wang, J., & Zhu, J. (2019) · Pharmaceutical Fronts · doi:10.1055/s-0039-1700507 · Cited by 22

Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers: an overview of clinical trial registry data from 2002 to 2022

Zhou, W., Xu, Z., Liu, S. Q., Lou, X., Liu, P., Xie, H., Zhang, S., Liu, X., Zhuo, B., & Huang, H. (2024) · BMC Cancer · doi:10.1186/s12885-024-12652-5 · Cited by 24

Current state of in vivo panning technologies: Designing specificity and affinity into the future of drug targeting

Gustafson, H. H., Olshefsky, A., Sylvestre, M., Sellers, D. L., & Pun, S. H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.015 · Cited by 23

Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy

Zhang, J., Liu, X., Xia, Y., Xu, S., Liu, X., Xiao, H., Wang, X., Liu, C., & Liu, G. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10482 · Cited by 20

Nanobody-mediated targeting of zinc phthalocyanine with polymer micelles as nanocarriers

Mesquita, B. S., Singh, A., Masdeu, C. P., Lokhorst, N., Hebels, E. R., van Steenbergen, M. J., Mastrobattista, E., Heger, M., van Nostrum, C. F., & Oliveira, S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124004 · Cited by 23

First platinum(II)-based metal-organic linker technology (Lx®) for a plug-and-play development of antibody-drug conjugates (ADCs)

Merkul, E., Sijbrandi, N. J., Muns, J. A., Aydin, I., Adamzek, K., Houthoff, H., Nijmeijer, B. A., & van Dongen, G. A. M. S. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1645118 · Cited by 21

Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression

Vasalou, C., Proia, T. A., Kazlauskas, L., Przybyła, A., Sung, M. S., Mamidi, S., Maratea, K., Griffin, M., Sargeant, R., Urosevic, J., et al. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13133 · Cited by 19

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer

Greene, M. K., Chen, T., Robinson, E., Straubinger, N. L., Minx, C., Chan, D. K. W., Wang, J., Burrows, J. F., Schaeybroeck, S. V., Baker, J. R., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01046-6 · Cited by 20

A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer

Jin, Y., Zhang, Z., Zou, S., Li, F., Chen, H., Peng, C., Deng, X., Wen, C., Shen, B., & Zhan, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.634881 · Cited by 18

Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance

Murali, M., Kumar, A. R., Nair, B., Pavithran, K., Devan, A. R., Pradeep, G., & Nath, L. R. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02707-5 · Cited by 21

Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates

Lu, N., Wu, J., Tian, M., Zhang, S., Li, Z., & Shi, L. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116233 · Cited by 19

Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma

McNamara, B. C., Greenman, M. P., Bellone, S., Santin, L. A., Demirkiran, C., Mutlu, L., Hartwich, T. M. P., Yang‐Hartwich, Y., Ratner, E., Schwartz, P. E., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.07.002 · Cited by 19

Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy

Mehrling, T., & Soltis, D. A. (2018) · Antibodies · doi:10.3390/antib7010011 · Cited by 19

Miniaturised ‘antibody’-drug conjugates for solid tumours?

Deonarain, M. P. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.09.006 · Cited by 19

Discovery of A Novel EGFR-Targeting Antibody–Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies

He, K., Xu, J., Liang, J., Jiang, J., Tang, M., Ye, X., Zhang, Z., Zhang, L., Fu, B., Li, Y., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0854 · Cited by 19

A refined cocktailing of pro-apoptotic nanoparticles boosts anti-tumor activity

Sánchez‐García, L., Sala, R., Serna, N., Álamo, P., Parladé, E., Alba‐Castellón, L., Voltà‐Durán, E., Sánchez‐Chardi, A., Unzueta, U., Vázquez, E., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.06.033 · Cited by 20

Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles

Voltà‐Durán, E., Serna, N., Sánchez‐García, L., Aviñó, A. M., Sánchez, J. M., López‐Laguna, H., Cano‐Garrido, O., Casanova, I., Mangues, R., Eritja, R., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.11.018 · Cited by 19

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma

Shemesh, C. S., Agarwal, P., Lu, T., Lee, C., Dere, R. C., Li, X., Li, C., Jin, J. Y., Girish, S., Miles, D., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04054-8 · Cited by 19

Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy

Deonarain, M. P., & Yahioglu, G. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1858050 · Cited by 18

The continuing role of chemotherapy in the management of advanced urothelial cancer

de Liaño, A. G., & Durán, I. (2018) · Therapeutic Advances in Urology · doi:10.1177/1756287218814100 · Cited by 18

Highly biocompatible carbon nanocapsules derived from plastic waste for advanced cancer therapy

Mezni, A., Saber, N. B., Alhadhrami, A., Gobouri, A. A., Aldalbahi, A. K., Hay, S. J., Santos, A., Lošić, D., & Altalhi, T. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.08.007 · Cited by 18

Antibody–Drug Conjugates (ADCs): A Review of Structural Design, Technological Evolution, and Future Perspectives

Wu, G., Yuan, Z., Chen, M., Tang, X., Wang, F., & Zhang, D. (2026) · Molecules · doi:10.3390/molecules31071180 · Cited by 17

Design, Synthesis, and Structure–Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody–Drug Conjugates

Chowdari, N. S., Zhang, Y., McDonald, I. M., Johnson, W. L., Langley, D. R., Sivaprakasam, P., Mate, R. A., Huynh, T., Kotapati, S., Deshpande, M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01385 · Cited by 17

Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration

Bussing, D., Li, Z., Li, Y., Chang, H.-P., Chang, H.-Y., Guo, L., Verma, A., & Shah, D. K. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00647-0 · Cited by 16

Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy

Zhang, S., Zhou, D., Zheng, C., Peng, X., Zhu, W., & Zheng, D. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.04.013 · Cited by 16

Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target

Mountzios, G., Saw, S. P. L., Hendriks, L. E. L., Menis, J., Cascone, T., Arrieta, O. G., Naidoo, J., Koutoukoglou, P., Cani, M., Lefevre, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102902 · Cited by 16

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma

Palma, B. D., Marchica, V., Catarozzo, M. T., Giuliani, N., & Accardi, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9093022 · Cited by 17

A branched small molecule-drug conjugate nanomedicine strategy for the targeted HCC chemotherapy

Li, S., Zhang, C., Wu, J., Liu, C., & Liu, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114037 · Cited by 16

The nuclear export inhibitor aminoratjadone is a potent effector in extracellular-targeted drug conjugates

Klahn, P., Fetz, V., Ritter, A., Collisi, W., Hinkelmann, B., Arnold, T., Tegge, W. J., Rox, K., Hüttel, S., Mohr, K. I., et al. (2019) · Chemical Science · doi:10.1039/c8sc05542d · Cited by 18

Antibody-drug conjugates for cancer therapy: An up-to-date review on the chemistry and pharmacology

Gholap, A. D., Gupta, J. S., Kamandar, P. A., Banchhod, G. V., & Hatvate, N. T. (2023) · Comprehensive analytical chemistry · doi:10.1016/bs.coac.2023.02.007 · Cited by 18

Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation

Zhao, C., Zhang, R., Yang, H., Gao, Y., Zou, Y., & Zhang, X. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116378 · Cited by 15

The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy

Zhou, M., Huang, Z., Ma, Z., Chen, J., Lin, S., Yang, X., Gong, Q., Braunstein, Z., Wei, Y., Rao, X., et al. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.49 · Cited by 17

Targeted Sonodynamic Destruction of Glioblastoma Cells Using Antibody–Titanium Dioxide Nanoparticle Conjugates

Lee, G. P., Willis, A. J., Pernal, S. P., Phakatkar, A. H., Shokuhfar, T., Blot, V., & Engelhard, H. H. (2021) · Nanomedicine · doi:10.2217/nnm-2020-0452 · Cited by 15

Mechanically interlocked functionalization of monoclonal antibodies

Bzymek, K. P., Puckett, J. W., Zer, C., Xie, J., Ma, Y., King, J. D., Goodstein, L. H., Avery, K. N., Colcher, D. M., Singh, G. P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03976-5 · Cited by 15

EGFR-Targeted Antibody–Drug Conjugate to Different Aminobisphosphonates: Direct and Indirect Antitumor Effects on Colorectal Carcinoma Cells

Pisheh, L., Matis, S., Taglieri, M., Gregorio, L. D., Benelli, R., & Poggi, A. D. (2024) · Cancers · doi:10.3390/cancers16071256 · Cited by 14

Increasing the Potential of the Auristatin Cancer-Drug Family by Shifting the Conformational Equilibrium

Sokka, I. K., Ekholm, F. S., & Johansson, M. P. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00437 · Cited by 14

Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries

Hsu, H.-J., Tung, C.-P., Yu, C.-M., Chen, C.-Y., Chen, H.-S., Huang, Y.-C., Tsai, P., Lin, S.-I., Peng, H.-P., Chiu, Y.-K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94902-1 · Cited by 11

Drug Design of “Undruggable” Targets

Wang, J., Li, S., & Li, H. (2019) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201800552 · Cited by 13

Research on Urban Community College Transfer and Retention: The Los Angeles TRUCCS Project.

Hagedorn, L. S., & Maxwell, B. (2002) · Cited by 13

Latest developments in photosensitizers: improving stability, specificity and responsiveness

Dong, J., Tang, J., Li, X., Zeng, Y., Su, X., He, Y., & Liu, X. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2515813 · Cited by 12

Novel antibody-drug conjugates based on DXd-ADC technology

Chen, R., Ren, Z., Bai, L., Hu, X., Chen, Y., Ye, Q., Hu, Y. J., & Shi, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107697 · Cited by 13

Targeting Ultrasmall Gold Nanoparticles with cRGD Peptide Increases the Uptake and Efficacy of Cytotoxic Payload

Perrins, R. D., McCarthy, L.-A., Robinson, A., Spry, K. L., Cognet, V., Ferreira, A., Porter, J. R., Garcı́a, C. E., Rodriguez, M. Á., Lopez, D., et al. (2022) · Nanomaterials · doi:10.3390/nano12224013 · Cited by 11

Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics

Dalziel, M., Beers, S. A., Cragg, M. S., & Crispin, M. (2018) · Glycobiology · doi:10.1093/glycob/cwy043 · Cited by 12

Recruiting potent membrane penetrability in tumor cell-targeted protein-only nanoparticles

Serna, N., Sánchez, J. M., Unzueta, U., Sánchez‐García, L., Sánchez‐Chardi, A., Mangues, R., Vázquez, E., & Villaverde, A. (2018) · Nanotechnology · doi:10.1088/1361-6528/aaf959 · Cited by 12

Conventional Nanosized Drug Delivery Systems for Cancer Applications

Vergallo, C., Hafeez, M. N., Iannotta, D., Santos, H. A., d’Avanzo, N., Dini, L., Cilurzo, F., Fresta, M., Marzio, L. D., & Christian, C. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_1 · Cited by 12

A novel strategy for treatment of bladder cancer: Antibody-drug conjugates

Kim, J. H., & Chang, I. H. (2022) · Korean journal of urology · doi:10.4111/icu.20220061 · Cited by 13

Modified Therapeutic Antibodies: Improving Efficacy

Dai, J., Zhang, X., Dai, J., Yang, X.-M., & Chen, Z. (2021) · Engineering · doi:10.1016/j.eng.2020.06.030 · Cited by 11

Antibody–Calixarene Drug Conjugate: A General Drug Delivery Platform for Tumor-Targeted Therapy

Wu, X., Yao, S., Huang, Q., Ying, A., Li, Q., Cao, X., Wang, C., Xiao, J. Z., Feng, N., Zhang, Z., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c09588 · Cited by 12

Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate

Chang, H. W., Wang, J., Liu, H., Xing, C., Chen, J., Frey, G., Boyle, W. J., & Short, J. M. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf006 · Cited by 11

Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody–Drug Conjugates (ADCs)

Mahmood, I. (2021) · Antibodies · doi:10.3390/antib10040040 · Cited by 11

Bispecific and Biparatopic Antibody Drug Conjugates

Comer, F. I., Gao, C., & Coats, S. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-78154-9_11 · Cited by 12

Fluctuations in dissolved oxygen concentration during a CHO cell culture process affects monoclonal antibody productivity and the sulfhydryl‐drug conjugation process

Hippach, M. B., Schwartz, I., Pei, J., Huynh, J., Kawai, Y., & Zhu, M. M. (2018) · Biotechnology Progress · doi:10.1002/btpr.2697 · Cited by 10

INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment

Bratti, M., Stubbs, E., Kolodych, S., Souchet, H., Kelly, L. M., Merlin, J., Marchal, M., Castellano, R., Josselin, E., Pasquer, H., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0548 · Cited by 10

Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors

Perino, S., Moreau, B., Freda, J., Cirello, A. L., White, B. H., Quinn, J. M., Kriksciukaite, K., Someshwar, A., Romagnoli, J., Robinson, M., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0964 · Cited by 10

Advances with antibody-drug conjugates in breast cancer treatment

Subhan, M. A., & Torchilin, V. P. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.10.016 · Cited by 10

Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy

Gouda, M. A., & Subbiah, V. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000627 · Cited by 12

The Evolving Landscape of Antibody–Drug Conjugates for Urothelial Carcinoma

Abel, M. L., Burkenroad, A., Sun, A., Lu, E., Stefanoudakis, D., & Drakaki, A. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.11.006 · Cited by 11

Personalized Immuno-Oncology

Jain, K. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-62080-6_20 · Cited by 11

Natural product–drug conjugates for modulation of TRPV1-expressing tumors

Baker, C., Rodrigues, T., de Almeida, B. P., Barbosa‐Morais, N. L., & Bernardes, G. J. L. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.03.025 · Cited by 9

Interspecies Scaling of Antibody–Drug Conjugates (ADC) for the Prediction of Human Clearance

Mahmood, I. (2021) · Antibodies · doi:10.3390/antib10010001 · Cited by 9

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

Qi, X., Li, Y., Liu, W., Wang, Y., Chen, Z., & Lizhu, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.921385 · Cited by 9

Antibody-Drug Conjugates Used in Breast Cancers

Abbas, A., Ibrahim, M. F., & Saifo, M. (2021) · Journal of Oncology · doi:10.1155/2021/9927433 · Cited by 9

Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2)

Seyedmirzaei, H., Keshavarz‐Fathi, M., Razi, S., Gity, M., & Rezaei, N. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155221991636 · Cited by 8

Pharmacokinetics of antibodies during pregnancy: General pharmacokinetics and pregnancy related physiological changes (Part 1)

Tegenge, M. A., Mahmood, I., Struble, E. B., & Sauna, Z. E. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109914 · Cited by 8

The Many Faces of Urothelial Carcinomas: An Update From Pathology to Clinical Approach and Challenges in Practice

Enneli, D., & Bağlan, T. (2023) · Urology Research and Practice · doi:10.5152/tud.2023.23023 · Cited by 8

Hybrid liquid chromatography high resolution and accuracy mass spectrometry approach for quantification of antibody-drug conjugates at the intact protein level in biological samples

Barbero, L. M., Ianni, A. D., Molinaro, F., Cowan, K. J., & Sirtori, F. R. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106502 · Cited by 8

Applications of SNAP‐tag technology in skin cancer therapy

Padayachee, E. R., Adeola, H. A., Wyk, J. C. V., Biteghe, F. A. N., Chetty, S., Khumalo, N. P., & Barth, S. (2019) · Health Science Reports · doi:10.1002/hsr2.103 · Cited by 8

Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy

Natarajan, A., Srinivas, S. M., Azevedo, E. C., Greene, L. R., Bauchet, A.-L., Jouannot, E., Lacoste-Bourgeacq, A.-S., Guizon, I., Cohen, P., Naneix, A.-L., et al. (2020) · Molecular Imaging · doi:10.1177/1536012120939398 · Cited by 8

Antibody-drug conjugates: an evolving approach for melanoma treatment

Anderson, T. S., McCormick, A. L., La-Beck, N. M., Saha, D., & Lowe, D. B. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000702 · Cited by 8

Engineered scPDL1-DM1 drug conjugate with improved in vitro analysis to target PD-L1 positive cancer cells and intracellular trafficking studies in cancer therapy

Kalim, M., Wang, S., Liang, K., Khan, M. S. I., & Zhan, J. (2019) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2018-0391 · Cited by 8

TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile

Vogl, A. M., Schmitt, S., Mai, I., Machui, P., Herterich, S., Leonardi, N., Cyprys, P., Hauswald, D., Ochtrop, P., Kozlowska, I., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0254 · Cited by 7

The investigational anti-B7-H3 antibody-drug conjugate vobramitamab duocarmazine exerts anti-tumor activity in vitro and in vivo in pediatric sarcoma preclinical models

Bianchi, G., Pastorino, F., Rolandi, G., Ciampi, E., Segalerba, D., Giovanni, B. D., Cafferata, B., Balbi, M., Ravera, S., Vellone, V. G., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08397-z · Cited by 7

Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes

Choi, W.-G., Park, R., Kim, D. K., Shin, Y., Cho, Y., & Lee, H. S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030220 · Cited by 7

Discovery research and translation science of trastuzumab deruxtecan, from non-clinical study to clinical trial

Nakada, T. (2021) · Translational and Regulatory Sciences · doi:10.33611/trs.2021-010 · Cited by 7

Possible Therapeutic Utility of anti-Cell Adhesion Molecule 1 Antibodies for Malignant Pleural Mesothelioma

Hagiyama, M., Mimae, T., Wada, A., Takeuchi, F., Yoneshige, A., Inoué, T., Kotoku, N., Hamada, H., Sekido, Y., Okada, M., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.945007 · Cited by 7

Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments

Nagayama, A., Ellisen, L. W., Chabner, B. A., & Bardia, A. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0535-0 · Cited by 103

Antibody-drug conjugates in solid tumors: a new frontier

Jaime‐Casas, S., Barragán-Carrillo, R., & Tripathi, A. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001064 · Cited by 8

Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload

Kondrashov, A., Sapkota, S., Sharma, A., Riaño, I., Kurzrock, R., & Adashek, J. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082160 · Cited by 50

Rise of Antibody-Drug Conjugates: The Present and Future

Shastry, M., Gupta, A., Chandarlapaty, S., Young, M. R., Powles, T. B., & Hamilton, E. P. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390094 · Cited by 113

Antibody–Drug Conjugates for Cancer Treatment

Lambert, J. M., & Berkenblit, A. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-061516-121357 · Cited by 315